Specialty medications account for 56% of total prescription drug spend. This will continue to rise.
ProAct is outperforming industry trends year after year.
Across ProAct's book of business in 2024, specialty plan spend decreased by 0.33% as compared to the industry average at a 12% increase.
We are committed to supporting our plan sponsors by offering solutions that help lower plan spend without sacrificing patient care.
Throughout our annual Drug Trend Report, we share both industry and ProAct specific information that helps validate our successes.
Is your specialty drug management strategy holding up?
ProAct's Winning Strategy
Through programs such as our Clinical Prior Authorization Management Program, we are able to ensure the most cost-effective therapies are being used. Coupling this with our formulary strategies — which are aimed to both drive lowest
net-cost therapies and encourage generic alternatives when appropriate — ProAct was able to stay below the trend
curve projected by industry experts.
Ready to compare your current plan against ProAct? There's no risk and it's completely free.
The Voice of Our Partners
At ProAct, our clients come first. Lots of PBMs say it – but we prove it every day with a culture built around caring, partnership and responsiveness. Don't just take our word for it! Here's what Marq Brown with Oswego Health had to say recently.
Proudly 100% Employee Owned
Being an Employee Stock Ownership Plan (ESOP) is so special because of our employees’ sense of ownership, engagement, commitment, and, most importantly, their sense of pride. It’s their pride not just in what they do, but how they do it.
Being an employee owner and personally sharing in the success of the company keeps employees tied to what matters most to our partners. It has developed a culture where our best interest is served by serving you and your clients' interest at the same time.